The terms and tone of the debate over human applications of somatic cell nuclear transfer, popularly known as cloning, are familiar to those who remember the politics of recombinant DNA in the 1970s. As the U.S. Senate begins what could be an historic debate on whether to allow SCNT to progress, Carl Feldbaum advocates the adoption of the kind of thoughtful, reasoned approach that allowed recombinant DNA to advance, resulting in therapies and vaccines for a multitude of afflictions.
No takes yet. Share an insight, caveat, or question.
Carl B. Feldbaum (2002) studied this question.